Atossa Therapeutics Files 8-K with Financials
Ticker: ATOS · Form: 8-K · Filed: Dec 10, 2024 · CIK: 1488039
| Field | Detail |
|---|---|
| Company | Atossa Therapeutics, INC. (ATOS) |
| Form Type | 8-K |
| Filed Date | Dec 10, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.18 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
Related Tickers: ATOS
TL;DR
ATOS filed an 8-K with financials, looks like standard reporting.
AI Summary
On December 10, 2024, Atossa Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine corporate activity rather than a specific event like an acquisition or major business change. No new material financial information or significant operational updates were disclosed in this particular filing.
Why It Matters
This filing indicates routine corporate reporting, suggesting no immediate material changes or significant events for Atossa Therapeutics, Inc. Investors should look to other filings for operational updates.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for financial statements and exhibits, not indicating any new risks or significant events.
Key Players & Entities
- Atossa Therapeutics, Inc. (company) — Registrant
- December 10, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 206.588.0256 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing by Atossa Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report financial statements and exhibits, as indicated by the 'ITEM INFORMATION' section.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on December 10, 2024.
What is the state of incorporation for Atossa Therapeutics, Inc.?
Atossa Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address for Atossa Therapeutics, Inc.?
The address of the Principal Executive Offices is 10202 5th Avenue NE, Suite 200, Seattle, Washington 98125.
Does this 8-K filing disclose any new material events or business changes?
Based on the provided text, this 8-K filing primarily concerns financial statements and exhibits, and does not explicitly disclose any new material events or significant business changes.
Filing Stats: 437 words · 2 min read · ~1 pages · Grade level 12.6 · Accepted 2024-12-10 09:05:08
Key Financial Figures
- $0.18 — ge on which registered Common Stock , $0.18 par value ATOS The Nasdaq Capital M
Filing Documents
- atos-20241210.htm (8-K) — 43KB
- atos-ex99_1.htm (EX-99.1) — 28KB
- img248274862_0.jpg (GRAPHIC) — 12KB
- 0000950170-24-134779.txt ( ) — 211KB
- atos-20241210.xsd (EX-101.SCH) — 28KB
- atos-20241210_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events On December 10, 2024, Atossa Therapeutics, Inc. issued a press release announcing the presentation of three posters involving pharmacokinetic and tolerability data from the Phase 2 EVANGELINE trial at the San Antonio Breast Cancer Symposium. A copy of the press release is filed as Exhibit 99.1 to this report and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit Number Description of Exhibit 99.1 Press release, dated December 10, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Atossa Therapeutics, Inc. Date: December 10, 2024 By: /s/ Heather Rees Chief Financial Officer